ATE253375T1 - Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes - Google Patents

Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes

Info

Publication number: ATE253375T1
Authority: AT; Austria
Prior art keywords: glp; upper gastrointestinal; gastrointestinal tract; methods; tissue
Prior art date: 1997-05-16

Application number

AT98922546T

Other languages

English (en)

Inventor

Daniel J Drucker

Original Assignee

Ontario Inc 1149336

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-16

Filing date

1998-05-15

Publication date

2003-11-15

1997-07-23 Priority claimed from GBGB9715481.9A external-priority patent/GB9715481D0/en

1998-04-13 Priority claimed from US09/059,504 external-priority patent/US6051557A/en

1998-05-15 Application filed by Ontario Inc 1149336 filed Critical Ontario Inc 1149336

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE253375T1 publication Critical patent/ATE253375T1/de

Links

102400000326 Glucagon-like peptide 2 Human genes 0.000 title abstract 6
101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 6
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 6
210000002438 upper gastrointestinal tract Anatomy 0.000 title abstract 5
239000000556 agonist Substances 0.000 title abstract 2
230000000694 effects Effects 0.000 title 1
239000000813 peptide hormone Substances 0.000 abstract 3
230000002496 gastric effect Effects 0.000 abstract 2
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
102400000321 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
210000003238 esophagus Anatomy 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
230000004968 inflammatory condition Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
210000002784 stomach Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Immunology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT98922546T 1997-05-16 1998-05-15 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes ATE253375T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US4675497P	1997-05-16	1997-05-16
GBGB9715481.9A GB9715481D0 (en)	1997-07-23	1997-07-23	Methods of enhancing functioning of the upper gastrointestinal tract
US09/059,504 US6051557A (en)	1997-05-16	1998-04-13	Methods of enhancing functioning of the upper gastrointestinal tract
PCT/CA1998/000497 WO1998052600A1 (en)	1997-05-16	1998-05-15	Methods of enhancing functioning of the upper gastrointestinal tract

Publications (1)

Publication Number	Publication Date
ATE253375T1 true ATE253375T1 (de)	2003-11-15

Family

ID=27268946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98922546T ATE253375T1 (de)	1997-05-16	1998-05-15	Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes

Country Status (13)

Country	Link
EP (1)	EP0981362B1 (de)
JP (2)	JP4699576B2 (de)
CN (1)	CN1264307B (de)
AT (1)	ATE253375T1 (de)
AU (1)	AU746633B2 (de)
BR (1)	BR9808804A (de)
CA (1)	CA2289652C (de)
DE (1)	DE69819488T2 (de)
DK (1)	DK0981362T3 (de)
ES (1)	ES2210756T3 (de)
MX (1)	MXPA99010523A (de)
PT (1)	PT981362E (de)
WO (1)	WO1998052600A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2210756T3 (es) *	1997-05-16	2004-07-01	1149336 Ontario Inc.	Utilizacion de agonistas del glp-2 para mejorar el funcionamiento del tracto gastrointestinal superior.
GB9905416D0 (en) *	1999-03-09	1999-05-05	Allelix Biopharma	Small molecules having GLP-2 like activity
RU2164349C1 (ru) *	1999-07-27	2001-03-20	Нижегородская государственная медицинская академия	Способ определения стоматологического статуса
WO2001041779A2 (en) *	1999-12-08	2001-06-14	1149336 Ontario Inc.	Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
WO2002022151A2 (en) *	2000-09-18	2002-03-21	Osteometer Bio Tech A/S	Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7186683B2 (en)	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2004035624A2 (en)	2002-10-14	2004-04-29	Novo Nordisk A/S	Glucagon - like peptide - 2 variants
US7847061B2 (en)	2004-11-01	2010-12-07	Nps Pharmaceuticals, Inc.	Treatment of short bowel syndrome patients with colon-in-continuity
MX2007013431A (es) †	2005-05-04	2008-01-18	Zealand Pharma As	Analogos del peptido 2 semejante al glucagon.
AU2007319066B2 (en) *	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
EP2337585A1 (de) *	2008-09-19	2011-06-29	Nektar Therapeutics	Polymerkonjugate von glp-2-artigen peptiden
EP2611825B1 (de)	2010-08-30	2015-09-02	NPS Pharmaceuticals, Inc.	Festphasensynthese von h(gly2)glp-2
TR201802689T4 (tr)	2012-05-03	2018-03-21	Zealand Pharma As	Glukagon benzeri peptit-2 (glp-2) analogları.
WO2016184427A1 (zh) *	2015-05-21	2016-11-24	中国科学院上海生命科学研究院	低氧处理的间充质干细胞及其应用
SG10201911851VA (en)	2016-12-09	2020-02-27	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists
ES2894629T3 (es)	2017-06-16	2022-02-15	Zealand Pharma As	Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
CN108273038B (zh) *	2018-03-16	2019-03-19	中国人民解放军军事科学院军事医学研究院	防治肠型放射病的药物组合物
CN110226566A (zh) *	2019-07-12	2019-09-13	南京中医药大学	一种放射性口腔黏膜炎动物模型的造模方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK27885A (da) *	1985-01-22	1986-07-23	Novo Industri As	Fremstilling af peptider
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
EP0906338B1 (de) *	1996-04-12	2002-11-06	1149336 Ontario Inc.	Analoge des glucagon ähnlichen peptides -2
DK1012186T3 (da) *	1996-12-06	2002-11-04	Amgen Inc	Keratinocyt-vækstfaktorer og anvendelser deraf
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
ES2210756T3 (es) *	1997-05-16	2004-07-01	1149336 Ontario Inc.	Utilizacion de agonistas del glp-2 para mejorar el funcionamiento del tracto gastrointestinal superior.

1998
- 1998-05-15 ES ES98922546T patent/ES2210756T3/es not_active Expired - Lifetime
- 1998-05-15 EP EP98922546A patent/EP0981362B1/de not_active Expired - Lifetime
- 1998-05-15 BR BR9808804-1A patent/BR9808804A/pt not_active Application Discontinuation
- 1998-05-15 PT PT98922546T patent/PT981362E/pt unknown
- 1998-05-15 CN CN988073307A patent/CN1264307B/zh not_active Expired - Fee Related
- 1998-05-15 AT AT98922546T patent/ATE253375T1/de active
- 1998-05-15 AU AU75163/98A patent/AU746633B2/en not_active Ceased
- 1998-05-15 DE DE69819488T patent/DE69819488T2/de not_active Expired - Lifetime
- 1998-05-15 WO PCT/CA1998/000497 patent/WO1998052600A1/en not_active Ceased
- 1998-05-15 CA CA2289652A patent/CA2289652C/en not_active Expired - Fee Related
- 1998-05-15 DK DK98922546T patent/DK0981362T3/da active
- 1998-05-15 JP JP54974198A patent/JP4699576B2/ja not_active Expired - Fee Related
- 1998-05-15 MX MXPA99010523A patent/MXPA99010523A/es active IP Right Grant
2009
- 2009-07-22 JP JP2009171401A patent/JP2009280598A/ja active Pending

Also Published As

Publication number	Publication date
JP4699576B2 (ja)	2011-06-15
BR9808804A (pt)	2001-09-18
AU746633B2 (en)	2002-05-02
CN1264307A (zh)	2000-08-23
PT981362E (pt)	2004-03-31
JP2002502369A (ja)	2002-01-22
CA2289652C (en)	2012-02-28
DK0981362T3 (da)	2004-03-15
HK1030160A1 (en)	2001-04-27
WO1998052600A1 (en)	1998-11-26
CA2289652A1 (en)	1998-11-26
AU7516398A (en)	1998-12-11
DE69819488D1 (de)	2003-12-11
EP0981362B1 (de)	2003-11-05
JP2009280598A (ja)	2009-12-03
WO1998052600A9 (en)	2000-03-09
ES2210756T3 (es)	2004-07-01
MXPA99010523A (es)	2004-09-01
DE69819488T2 (de)	2004-08-26
CN1264307B (zh)	2013-10-30
EP0981362A1 (de)	2000-03-01

Legal Events

Date

Code

Title

Description

2004-07-15

UEP

Publication of translation of european patent specification

Ref document number: 0981362

Country of ref document: EP

Publication	Publication Date	Title
DE69819488D1 (de)	2003-12-11	Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
ATE233096T1 (de)	2003-03-15	Zusammensetzungen und methoden zur steigerung der darmfunktion
Lundy et al.	2004	Neuropeptides and neurogenic mechanisms in oral and periodontal inflammation
UA42747C2 (uk)	2001-11-15	Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
ATE450269T1 (de)	2009-12-15	Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE69914932D1 (de)	2004-03-25	Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
DE69736634D1 (de)	2006-10-19	Antagonisten des intestinotrophen glp-2 peptides
DE69521796D1 (de)	2001-08-23	Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndromes
TR199801649T2 (xx)	1998-12-21	Ba��kl�k mod�lasyonu i�in farmaz�tik bile�imler.
HUP0004560A2 (hu)	2001-04-28	Törést gyógyító PTHrP analógok
WO1998033509A3 (en)	1999-03-11	Useful properties of human lactoferrin and variants thereof
DE60118723D1 (de)	2006-05-24	Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
ATE531382T1 (de)	2011-11-15	Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
DE69435096D1 (de)	2008-06-12	Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
EA200400376A1 (ru)	2005-06-30	Пептиды, полученные из казеина, и их использование в терапии
EA200100872A1 (ru)	2002-02-28	Композиция валдекоксиба
DE69607750D1 (de)	2000-05-18	Aminosäurenzusammensetzungen und verwendung derselben klinischen nährung
ATE230417T1 (de)	2003-01-15	Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE60237158D1 (de)	2010-09-09	Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
WO2004027064A3 (en)	2004-11-18	Ghrh analogues
JP2006506942A5 (de)	2006-04-13
ATE280777T1 (de)	2004-11-15	Bradykinin-antagonist peptide mit n- substituierten glycinen
ATE425763T1 (de)	2009-04-15	Verwendung von zusammensetzungen mit der biologischen aktivitat der vasoaktiven intestinalen peptide zur behandlung von sarcoidose
TR200103339T2 (tr)	2002-04-22	Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri.
NO20011537L (no)	2001-05-28	Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes